Patent Number: 8,815,292

Title: Compositions and methods for treating insulin resistance and diabetes mellitus

Abstract: Provided are electrokinetically-altered fluids (gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating diabetes and diabetes-associated conditions or disorders (e.g., insulin resistance), or symptoms thereof. Provided are electrokinetically-altered ioinic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) and therapeutic compositions.

Inventors: Watson; Richard L. (McPherson, KS), Wood; Anthony B. (Dallas, TX), Archambeau; Gregory J. (Puyallup, WA)

Assignee: Revalesio Corporation

International Classification: A61K 31/58 (20060101); A61K 9/14 (20060101); A61P 29/00 (20060101); A61P 3/10 (20060101); A61K 31/138 (20060101)

Expiration Date: 8/26/12018